Geroscience is a research paradigm based in understanding the genetic, molecular and cellular mechanisms that make aging a major risk factor for and driver of common chronic conditions and diseases of older people. Geroscience research seeks to understand how aging affects the disease process and to use that knowledge to slow the rate of aging, reverse its effects, and delay or even cure age-related diseases.
The Translational Geroscience Network (TGN) is a collaboration of researchers looking at clinical interventions that target fundamental mechanisms of aging to delay, prevent or treat age-related diseases and disabilities as a group, instead of one at a time.
Network Clinical Trials
The Translational Geroscience Network (TGN) maintains this list of clinical trials in which the network is directly involved. This list, including most of its section headers, are dynamically updated with detail by clinicaltrials.gov to showcase the Network's progress, collaboration, and expansion. This list can be searched or exported as a spreadsheet.
| NCT # | Title | Acronym | Status | Publications | Stored Specimens | Conditions | Interventions | Outcome Measures | Sponsor Collaborators | Gender | Age | Phases | Enrollment | Funded Bys | Study Type | Study Designs | Other IDs | Start Date | Primary Completion Date | Completion Date | First Posted | Results First Posted | Last Update Posted | Locations | Study Documents | URL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05025956 | Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan | Active, not recruiting | Femoroacetabular Impingement | Drug: Fisetin|Drug: Placebo | Incidence of Treatment-Emergent Adverse Events|Patient Reported Outcomes Questionnaire-Modified Harris Hip Score (mHHS)|Patient Reported Outcomes Questionnaire- Hip Outcome Score: activities of daily living and sports subscales (HOS-ADL, HOS-SSS)|Patient Reported Outcomes Questionnaire-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Patient Reported Outcomes Questionnaire-Optum Short Form physical and mental component scores (SF-12 PCS and SF-12 MCS)|Patient Reported Outcomes Questionnaire-Tegner Activity Scale|Patient Reported Outcomes Questionnaire-Numeric Rating Scale for Hip Pain|Patient Reported Outcomes Questionnaire-Patient satisfaction with surgical outcome|Multi and singleplex immunoassays and flow cytometry senescence and SASP marker assessment of peripheral blood|Incidence of revision arthroscopy or other hip surgery required post initial arthroscopy | Steadman Philippon Research Institute|United States Department of Defense | All | 18 Years to 80 Years † (Adult, Older Adult) | Phase 1|Phase 2 | 68 | Other|U.S. Fed | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | 2020-058 | October 24, 2021 | October 31, 2024 | October 31, 2024 | August 30, 2021 | April 16, 2024 | The Steadman Clinic, Vail, Colorado, United States | https://ClinicalTrials.gov/show/NCT05025956 | |||||
| NCT05758246 | Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial | Recruiting | Sepsis|Acute Infection|Organ Failure | Drug: Fisetin-dose 1|Drug: Fisetin-dose 2|Drug: Placebo | Difference in the composite cardiovascular, respiratory, and renal sequential organ failure assessment (CRR-SOFA)|Safety of 2 doses of fisetin in patients with mild sepsis|Organ failure free days|Total SOFA score|Zubrod performance status|SF-12 score|Days in the ICU|All-cause mortality|Peripheral CD3+ senescent (SnCs) immune cells|Outcome is the relative expression of p16Ink4a in CD3+ cells.|TNF-alpha | University of Minnesota | All | 65 Years and older † (Older Adult) | Phase 2 | 220 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | HRP-XXX | August 23, 2023 | August 23, 2026 | August 23, 2026 | March 7, 2023 | April 18, 2024 | Ridges, Burnsville, Minnesota, United States|Southdale, Edina, Minnesota, United States|St. John's, Maplewood, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|HCMC, Minneapolis, Minnesota, United States|UMMC, Minneapolis, Minnesota, United States | https://ClinicalTrials.gov/show/NCT05758246 | |||||
| NCT05595499 | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | Recruiting | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8 | Procedure: Biospecimen Collection|Drug: Fisetin|Drug: Placebo Administration|Other: Quality-of-Life Assessment|Other: Questionnaire Administration | Change in 6-minute walk distance (6MWD)|Change in grip strength|Change in Short Physical Performance Battery score|Change in frailty phenotype|Change in physical function component of 36-item Short Form (SF-36)|Change in the Borg Rating of Perceived Exertion score|Change in Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 scores|Change in Patient Reported Outcomes Measurement Information System cognitive function short form score|Change in composite SF-36 score|Change in sleep (Insomnia Severity Index score)|Change in anxiety (Generalized Anxiety Disorder-7 score)|Change in depression (Patient Health Questionnaire-8 score)|Local recurrence free survival|Distant recurrence free survival|Breast cancer specific survival and overall survival|Overall survival|Adverse events rates|Adherence rate | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|National Institute on Aging (NIA) | Female | Child, Adult, Older Adult | Phase 2 | 88 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 23-001170|NCI-2022-08061|P30CA016042|R21CA277660|K76AG074918 | March 27, 2023 | June 1, 2026 | June 1, 2026 | October 27, 2022 | April 16, 2024 | City of Hope Comprehensive Cancer Center, Duarte, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States | https://ClinicalTrials.gov/show/NCT05595499 | |||||
| NCT05593588 | Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency | Enrolling by invitation | Common Variable Immunodeficiency|Interstitial Lung Disease Due to Systemic Disease | Drug: Fisetin|Drug: Placebo | Change in immunophenotyping of peripheral T lymphocytes|Change in Forced Vital Capacity (FVC)|Change in radiologic imaging in subjects|Use of MRI imaging for assessment of GLILD|Infectious complications|Adverse Events|Change in quality of life|Change in 6 minute walk test | Avni Joshi|Mayo Clinic | All | 18 Years and older † (Adult, Older Adult) | Phase 2 | 20 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 21-003119 | April 12, 2023 | December 2024 | December 2024 | October 25, 2022 | April 14, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT05593588 | |||||
| NCT05422885 | Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease | STAMINA | Completed | Aging | Drug: Dasatinib|Drug: Quercetin | Neurovascular coupling|Executive function|Gait speed|Physical performance|Mobility|Grip strength|Gait speed during cognitive task|Senescent CD3 cells expressing p16|SASP factors in blood and urine | Lewis Lipsitz|Hebrew SeniorLife | All | 65 Years and older † (Older Adult) | Phase 1|Phase 2 | 12 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention | Pro00053594 | May 20, 2022 | January 24, 2024 | January 24, 2024 | June 21, 2022 | March 7, 2024 | Hebrew Senior Life, Boston, Massachusetts, United States | "Study Protocol and Informed Consent Form", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT05422885/Prot_ICF_000.pdf|"Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT05422885/SAP_001.pdf | https://ClinicalTrials.gov/show/NCT05422885 | |||
| NCT05416515 | A Study of Fisetin to Treat Carpal Tunnel Syndrome | Recruiting | Carpal Tunnel Syndrome | Drug: Fisetin | Change in CTS symptoms|percent decrease in blood markers of cellular senescence, e.g., p16, IL-6, IL-15, TNF, PAI-1, ICAM-1, and additional exploratory, novel assays|percent decrease in blood markers of cellular senescence in long-term | Peter C. Amadio, M.D.|Mayo Clinic | All | 21 Years to 80 Years † (Adult, Older Adult) | Phase 2 | 40 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 21-010406 | October 9, 2022 | December 2024 | December 2025 | June 13, 2022 | November 1, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT05416515 | |||||
| NCT05362786 | Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease | Active, not recruiting | Chronic Kidney Diseases | Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC) | Adverse events and/or serious adverse events|Change in eGFR Value | LaTonya J. Hickson|Mayo Clinic | All | 30 Years to 80 Years † (Adult, Older Adult) | Phase 1 | 14 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 21-011822 | July 1, 2022 | November 2024 | February 2025 | May 5, 2022 | April 19, 2024 | Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT05362786 | |||||
| NCT04869761 | Stem Cell Therapy for Chronic Kidney Disease | Active, not recruiting | Chronic Kidney Diseases|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Diabetic Nephropathies | Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions | Adverse events and/or serious adverse events | LaTonya J. Hickson|Mayo Clinic | All | 30 Years to 80 Years † (Adult, Older Adult) | Phase 1 | 10 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other | 20-008380 | October 7, 2021 | December 2026 | December 2026 | May 3, 2021 | November 30, 2023 | Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04869761 | |||||
| NCT04815902 | Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis | Active, not recruiting | Osteoarthritis, Knee | Drug: Fisetin|Drug: Losartan|Drug: Placebo - Losartan|Drug: Placebo Fisetin | Incidence of Treatment-Emergent Adverse Events|Morphological and Quantitative Magnetic Resonance Imaging (MRI)|Evaluation of patient reported outcome (PRO) for quality of life|Evaluation of patient reported outcome (PRO) for knee functions (WOMAC)|Evaluation of patient reported outcome (PRO) for knee functions (Tegner)|Evaluation of patient reported outcome (PRO) for knee functions (IKDC)|Patient-Reported Outcome Questionnaires|Change in muscle strength of the study knee|Change in physical function of the Study Knee (LEK)|Change in physical function of the Study Knee (Stair Test)|Change in physical function of the Study Knee (fast 40-meter walk)|Change in physical function of the Study Knee (TUG)|Change in physical function of the Study Knee (6-minute walk test)|Change in associate biomarkers as compared to placebo in peripheral blood plasma/serum|Change in CTX-II as compared to placebo in urine|Change in levels of senescent PBMCS (total and specific PBMC subsets such as T-Cells)|Change in synovial fluid content|Characterization of Bone Marrow Derived Aspirate Concentrate cell content prior to injection|Characterization of Bone Marrow Derived plasma biomarkers prior to injection|Change in time to conversion to alternative treatment | Steadman Philippon Research Institute|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | All | 40 Years to 85 Years † (Adult, Older Adult) | Phase 1|Phase 2 | 100 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | 2020-15|1UG3AR077748-01 | May 18, 2021 | February 1, 2025 | June 1, 2025 | March 25, 2021 | April 16, 2024 | The Steadman Clinic, Vail, Colorado, United States | https://ClinicalTrials.gov/show/NCT04815902 | |||||
| NCT04785300 | ALSENLITE: Senolytics for Alzheimer's Disease | Enrolling by invitation | PMID: 34366147 | Mild Cognitive Impairment|Alzheimer Disease | Drug: Dasatinib|Drug: Quercetin | Safety and Tolerability of 11 week of intermittent D+Q treatment | James L. Kirkland, MD, PhD|Mayo Clinic | All | 55 Years and older † (Adult, Older Adult) | Phase 1|Phase 2 | 20 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 19-003394 | July 6, 2022 | December 2024 | December 2024 | March 5, 2021 | March 18, 2024 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04785300 | ||||
| NCT04733534 | An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer | Recruiting | Frailty|Childhood Cancer | Drug: Dasatinib plus Quercetin|Drug: Fisetin | Change in walking speed|Change in Walking Speed|Senescent cell abundance in blood (p16INK4A)|Safety of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0|Tolerability of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 | St. Jude Children's Research Hospital|National Institutes of Health (NIH)|National Cancer Institute (NCI) | All | 18 Years and older † (Adult, Older Adult) | Phase 2 | 60 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | SENSURV|U01CA246510 | June 6, 2022 | December 2024 | December 2025 | February 2, 2021 | August 2, 2023 | St. Jude Children's Research Hospital, Memphis, Tennessee, United States | https://ClinicalTrials.gov/show/NCT04733534 | |||||
| NCT04537299 | COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes | COVID-FIS | Active, not recruiting | PMID: 34375437 | Covid19|SARS-CoV Infection | Drug: Fisetin|Drug: Placebo | Change in COVID-19 Severity | Mayo Clinic|National Institute on Aging (NIA) | All | 65 Years and older † (Older Adult) | Phase 2 | 20 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 20-008867|1R01AG072301-01 | April 29, 2022 | August 31, 2024 | November 30, 2024 | September 3, 2020 | April 11, 2024 | Mayo Clinic, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04537299 | |||
| NCT04476953 | COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation | Enrolling by invitation | Covid19 | Drug: Placebo|Drug: Fisetin | Serious Adverse Events|Change in oxygenation status|CoV Severity Category | Mayo Clinic | All | 18 Years and older † (Adult, Older Adult) | Phase 2 | 80 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 20-003936 | August 3, 2020 | December 2024 | September 2025 | July 20, 2020 | February 16, 2024 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04476953 | |||||
| NCT04313634 | Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans | Active, not recruiting | Healthy | Drug: Dasatinib|Drug: Quercetin|Drug: Fisetin | Percent Changes in C-terminal telopeptide of type I collagen [CTX]|Percent changes in bone turnover markers|BMD changes|Plasma SASP factors | Sundeep Khosla, M.D.|Mayo Clinic | Female | 60 Years and older † (Adult, Older Adult) | Phase 2 | 120 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care | 18-010546 | June 9, 2020 | June 6, 2023 | June 6, 2024 | March 18, 2020 | March 27, 2024 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT04313634 | |||||
| NCT04235309 | Physical Resilience: Indicators and Mechanisms in the Elderly (PRIME) Collaborative Phase 2 | PRIME-Knee | Completed | Resilience|Aging | Change in musculoskeletal resiliency following orthopedic surgery as measured by physical activity (step counts)|Change in musculoskeletal resiliency following orthopedic surgery as measured by Lower Extremity Physical Activities of Daily Living (LE PADLs)|Change in musculoskeletal resiliency following orthopedic surgery as measured by PROMIS Pain Intensity|Change in musculoskeletal resiliency following orthopedic surgery as measured by PROMIS Pain Interference|Change in cognitive resiliency following orthopedic surgery as measured by 3D-CAM.|Change in cognitive resiliency following orthopedic surgery as measured by cognitive change index (CCI) for patient.|Change in cognitive resiliency following orthopedic surgery as measured by cognitive change index (CCI) for informant about patient.|Change in association between in vitro immune resiliency and resilient outcomes following elective orthopedic surgery.|Change in dual task gait speed|Change in tissue oxygenation index (TOI)|Intraoperative electrocardiography (ECG) RR variability | Duke University|National Institute on Aging (NIA) | All | 60 Years and older † (Adult, Older Adult) | 297 | Other|NIH | Observational | Observational Model: Cohort|Time Perspective: Prospective | Pro00103483|4UH3AG056925-03 | February 27, 2020 | October 30, 2023 | October 30, 2023 | January 21, 2020 | March 25, 2024 | Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States | https://ClinicalTrials.gov/show/NCT04235309 | ||||||
| NCT04176133 | Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination | Completed | Healthy | Drug: Entolimod|Drug: Placebo|Drug: Influenza vaccine | Change in Anti- A/H1N1 Antibody Titer|Change in Anti-A/H3N2 Antibody Titer|Change in Anti-B Antibody Titer|Adverse Events|Time of Onset for Upper-respiratory Infections|Upper Respiratory Infections|Change in Frailty|Change in 6-minute Walk Test|Change in Grip Strength|Change in Body Mass Index (BMI) | Robert J. Pignolo|Genome Protection, Inc|Mayo Clinic | All | 65 Years and older † (Older Adult) | Phase 2 | 61 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention | 19-004847 | October 30, 2019 | March 30, 2022 | March 30, 2022 | November 25, 2019 | June 22, 2023 | June 22, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | "Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/33/NCT04176133/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT04176133 | |||
| NCT04063124 | Senolytic Therapy to Modulate Progression of Alzheimer's Disease | SToMP-AD | Completed | PMID: 34687726 PMID: 35098970 | Alzheimer Disease | Drug: Dasatinib + Quercetin | Brain Penetrance of Dasatinib (D)|Brain Penetrance of Quercetin (Q)|Alzheimer's Disease Marker - CSF Tau|Alzheimer's Disease Marker - CSF Amyloid Beta|Senescence Marker IL-6 in CSF|Senescence Marker P16 in CSF|Electronic Gait Mapping Under Single and Dual-task Conditions|Montreal Cognitive Assessment (MoCA) | The University of Texas Health Science Center at San Antonio|Mayo Clinic | All | 65 Years and older † (Older Adult) | Phase 1|Phase 2 | 5 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | HSC20190222H | February 14, 2020 | December 10, 2021 | January 30, 2023 | August 21, 2019 | March 6, 2023 | March 6, 2023 | Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States | "Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT04063124/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT04063124 | |
| NCT03840343 | Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease | Terminated | Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Chronic Kidney Disease|Diabetic Nephropathy Type 2|Kidney Failure|Kidney Insufficiency | Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose | Adverse Events|Kidney Function | Mayo Clinic|Regenerative Medicine Minnesota | All | 45 Years to 75 Years † (Adult, Older Adult) | Phase 1 | 2 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 18-002423|RMM 091718 CT 001 | October 23, 2019 | August 4, 2020 | August 4, 2020 | February 15, 2019 | April 5, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03840343 | |||||
| NCT03818802 | Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging | Recruiting | Healthy Elderly Volunteers | Dietary Supplement: Nicotinamide Riboside|Dietary Supplement: Placebo | Maximal oxygen uptake (VO2 max) test|Skeletal muscle function|Short Physical Performance Battery (SPPB)|Respiration rate on muscle biopsy samples|PCR on muscle biopsy samples|Immunoblot on muscle biopsy samples|Bone metabolism|Glucose profile|Insulin|Lipid profile|Hemoglobin A1C|Oral glucose tolerance test | Mayo Clinic | Female | 65 Years to 80 Years † (Older Adult) | Not Applicable | 48 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention | 18-000224 | September 16, 2019 | December 2024 | December 2024 | January 28, 2019 | April 19, 2024 | Mayo Clinic, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03818802 | |||||
| NCT03675724 | Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | AFFIRM-LITE | Enrolling by invitation | Frail Elderly Syndrome | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Decrease in blood inflammation markers | Mayo Clinic | All | 70 Years and older † (Older Adult) | Phase 2 | 40 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 18-007332 | November 15, 2018 | June 2024 | October 2024 | September 18, 2018 | February 16, 2024 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03675724 | ||||
| NCT03430037 | Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | AFFIRM | Enrolling by invitation | Frail Elderly Syndrome | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Improved 6 minute walk | Mayo Clinic | Female | 70 Years and older † (Older Adult) | Phase 2 | 40 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 17-000472 | February 6, 2018 | June 2024 | October 2024 | February 12, 2018 | February 16, 2024 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03430037 | ||||
| NCT03325322 | Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease | Suspended | Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization | Mayo Clinic | All | 40 Years to 80 Years † (Adult, Older Adult) | Phase 2 | 30 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | 16-010521 | January 2, 2018 | December 2025 | December 2026 | October 30, 2017 | April 19, 2024 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT03325322 | |||||
| NCT02874989 | Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial | IPF | Completed | PMID: 30616998 | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Dasatinib + Quercetin|Drug: Placebo | Percentage of pro-inflammatory expressing cells|Blood Pressure|Weight|Heart Rate|CBC (complete blood count)|Lipid Panel|HbA1c (glycated hemoglobin)|CMP (comprehensive metabolic panel)|Plasma hsCRP (high-sensitivity C-reactive protein)|Plasma IL-6 (inflammatory biomarker)|Plasma IL-6R (inflammatory biomarker)|Plasma PASP biomarkers (inflammatory biomarkers)|p16INK4a biomarker (inflammatory biomarker) | Wake Forest University Health Sciences|Mayo Clinic|The University of Texas Health Science Center at San Antonio | All | 50 Years and older † (Adult, Older Adult) | Phase 1 | 26 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science | IRB00037000 | December 16, 2016 | June 3, 2019 | June 3, 2019 | August 22, 2016 | May 12, 2020 | Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Texas Health Science Center, San Antonio, Texas, United States | "Informed Consent Form", https://classic.clinicaltrials.gov/ProvidedDocs/89/NCT02874989/ICF_000.pdf | https://ClinicalTrials.gov/show/NCT02874989 | ||
| NCT02848131 | Senescence in Chronic Kidney Disease | Enrolling by invitation | PMID: 31542391 PMID: 35615688 | Chronic Kidney Disease | Drug: Group 2: Dasatinib|Drug: Group 2: Quercetin | Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function | Mayo Clinic | All | 40 Years to 80 Years † (Adult, Older Adult) | Phase 2 | 30 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 15-005843 | July 2016 | April 2025 | April 2025 | July 28, 2016 | April 19, 2024 | Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States | "Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT02848131/Prot_SAP_001.pdf | https://ClinicalTrials.gov/show/NCT02848131 | |||
| NCT02652052 | Hematopoietic Stem Cell Transplant Survivors Study | Recruiting | Stem Cell Transplant | Other: Standard of Care - Observation Only|Drug: Group 2: Quercetin|Drug: Group 2: Dasatinib | Frailty | Mayo Clinic | All | 18 Years and older † (Adult, Older Adult) | Not Applicable | 10 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care | 15-004683|NCI-2021-14235 | March 1, 2016 | October 15, 2024 | October 15, 2024 | January 11, 2016 | November 18, 2023 | Mayo Clinic in Rochester, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT02652052 | |||||
| NCT04771611 | COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications | COVFIS-HOME | Completed | Covid19|Coronavirus Infection | Drug: Fisetin|Drug: Placebo | World Health Organization (WHO) Ordinal Scale Score|Serious Adverse Events | James L. Kirkland, MD, PhD|Mayo Clinic | All | 18 Years and older † (Adult, Older Adult) | Phase 2 | 55 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | 20-009705 | July 14, 2021 | September 27, 2022 | September 27, 2022 | February 25, 2021 | August 1, 2023 | August 1, 2023 | Mayo Clinic, Rochester, Minnesota, United States | "Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/11/NCT04771611/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT04771611 | ||
| NCT04685590 | Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study | SToMP-AD | Recruiting | PMID: 34366147 PMID: 34687726 | Alzheimer Disease, Early Onset|Mild Cognitive Impairment | Drug: Dasatinib + Quercetin|Other: Placebo Capsules | Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group|Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score|Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood|Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood|Change in cellular senescence blood marker T cells in blood|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope|Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope|Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology | Wake Forest University Health Sciences|The University of Texas Health Science Center at San Antonio | All | 65 Years and older † (Older Adult) | Phase 2 | 48 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | IRB00067429 | December 22, 2021 | January 2025 | January 2026 | December 28, 2020 | December 14, 2023 | Wake Forest Health Sciences, Winston-Salem, North Carolina, United States|FundaciÛn ACE Clinical Site, Barcelona, Spain|Hospital ClÌnic de Barcelona Site, Barcelona, Spain|Sant Pau Clinical Site, Barcelona, Spain|FISEVI Clinical Site, Sevilla, Spain | https://ClinicalTrials.gov/show/NCT04685590 | |||
| NCT04210986 | Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial | Completed | Osteoarthritis, Knee | Dietary Supplement: Fisetin|Drug: Placebo oral capsule | Incidence of Treatment-Emergent Adverse Events|Change in levels of pro-inflammatory markers associated with Senescence|Change in levels of cartilage degenerating markers associated with OA|Change in physical function of the Study Knee (6 min walk)|Change in physical function of the Study Knee (timed-up-and-go test)|Change in physical function of the Study Knee (fast 40-meter walk)|Change in physical function of the Study Knee (LEK)|Change in physical function of the Study Knee (Chair Test)|Change in muscle strength (Isokinetic Dynamometry)|Evaluation of patient reported outcomes (PROs) for knee pain|Evaluation of patient reported outcomes (PROs) for knee function|Change in the quality of articular cartilage in the Study Knee with quantitative magnetic resonance imaging (MRI)|Change in time to conversion to alternative treatment | Steadman Philippon Research Institute|United States Department of Defense|Office of Naval Research (ONR) | All | 40 Years to 80 Years † (Adult, Older Adult) | Phase 1|Phase 2 | 75 | Other|U.S. Fed | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | 2019-16 | January 6, 2020 | January 5, 2023 | February 1, 2023 | December 26, 2019 | January 18, 2024 | The Steadman Clinic, Vail, Colorado, United States | https://ClinicalTrials.gov/show/NCT04210986 |
* All data provided by clinicaltrials.gov except publication and stored specimen columns. Data display last updated on Apr 22, 2024 11:59:50 AM